The promise of AI:
Better day to day lives for patients.
pulseData uses patented AI to better diagnose, risk stratify, and predict adverse events for patients with chronic disease or disorders involving both the heart and kidneys.
We all need luck but we can’t rely on it to pave the way to personal and financial health.
pulseData’s AI platform
We are the only company focused solely on the impact technology can have on kidney care. Our advanced artificial intelligence models have the highest performance in the market, building on our patented machine learning system for predicting risk of renal decline.
Process only the data needed to improve care and get data from key sources to close information gaps.
Patented Artificial Intelligence
Nuanced models specific to individual patients, trained on millions on complex patient journeys, predict cardiorenal disease progression.
Understand the risk progression for each patient, with a disease specific care summary and highlighting interventions needed to improve care.
Directing the right patients to the right program at the right time maximizing the performance of your care team.
A better way to understand your patients
"In a perfect world data for KFRE would be available in every clinic/health system. But the perfect world doesn’t exist, not even in neph clinics, let alone health systems. For the real world, pulseData has the best solution on the market by miles."
- Dr. Navdeep Tangri, Physician and the lead researcher and creator of the predictive model for progression of chronic kidney disease to kidney failure (KFRE)
“pulseData helped us act quickly to build a safety net for all our members and proactively intervene with those most at-risk. We’re excited about the benefits this partnership will bring to our members and primary care practices moving forward.”
- Faris Ghawi, CEO of Vytalize
“Pain-point targeted technology:…startups focused on solving specific pain points can find success in helping risk takers target niche opportunities. For example pulseData uses AI & ML to understand patient data and predict outcomes for chronic kidney disease and end-stage renal disease. By targeting kidney care, which accounts for roughly 20% of CMS spending, pulseData can potentially provide quick wins to customers. Risk-takers will use these savings to further invest in VBC technology."
- Pitchbook 2021 Annual Enterprise Healthtech Report
"The future of healthcare will depend on leveraging advanced technologies that keep patients healthier and costs lower. pulseData is focused on having exactly this impact on renal disease, a chronic condition that affects millions of patients and costs the healthcare system over $100 billion a year. We're excited to continue our partnership with such a brilliant and mission-driven team of entrepreneurs."
- Mike Goguen, Founder and Managing Partner of Two Bear Capital.
“pulseData has built the best data intelligence platform for predicting the progression of kidney disease. pulseData’s models equip local care teams to deliver the highest quality care to the most at-risk patient cohorts. We’re excited about the results pulseData has achieved. We look forward to partnering with Teddy, Hai Po and the rest of the management team to improve kidney care for patients.”
- Danielle Wang, Senior Vice President at Bain Capital
We work with the best minds in kidney care.
Diagnostics is both an art and a science. With AI supporting their processes, physicians are able to cut through the noise and dial in on some of the more uncommon elements that make diagnosing patients so very complex. A partnership between clinicians and algorithms means physicians have more real and relevant data at scale; on hand and in time to improve more lives, with better diagnoses.
Better curation of underlying data, (for example phenotyping) can be used to avoid potentially inherent biases and to generate more transparency in the data and algorithms. When people are not buried in a number, the impact is triumphant; trust and understanding emerge as do the people who are at risk and would have gone unseen or misdiagnosed, otherwise. This clarity is core to better care quality, efficiency and impact.
Awareness of kidney disease is personal. Thirty-seven million Americans have chronic kidney disease, and only 10 percent of them know it.